Table 1.
Summary of patient and study characteristics among populations of patients with rheumatoid arthritis
| All Populations | Traditional DMARD naïve | Traditional DMARD experienced | TNF Experienced | |
|---|---|---|---|---|
| Number of trials | 106 (100%) | 24 (22.6%) | 71 (67%) | 11 (10.4%) |
| No. of patients in trials | 42,330 (100%) | 8,375 (19.8%) | 29,167 (68.9%) | 4,788 (11.3%) |
| No. of patients with serious infection | 965 (100%) | 227 (23.5%) | 646 (66.9%) | 92 (9.5%) |
| Median year of Publication (range) | 2008 (1992-2013) | 2006 (1992-2013) | 2008 (1994-2013) | 2008 (2005-2013) |
| No. of treatment nodes | 10 | 5 | 10 | 6 |
| No. of 2-arm trials | 63 | 19 | 38 | 6 |
| No. of multi-arm trials | 43 | 5 | 33 | 5 |
| Mean follow-up duration, months (range) | 9 (1,60) | 13.1 (3,24) | 8 (1,60) | 6.3 (2,12) |
| Trials with duration ≥12 months | 33 (31.1%) | 17 (70.8%) | 18 (25.4%) | 2 (18.2%) |
| Mean RA duration, years (range) | 6.9 (0.1,13.5) | 0.7 (0.1,3.5) | 8.5 (2.2,13.5) | 10.8 (6.4,12.9) |
| Mean annualized baseline risk of serious infection in traditional DMARDs | 2% (0%, 9.2%) | 2% (0%, 9.2%) | 2% (0%, 8%) | 2.4% (0%, 4.5%) |
DMARD= disease-modifying anti-rheumatic drugs; MTX=methotrexate; RCT=randomized controlled trial; TNF= Tumor necrosis factor
* Only included trials greater than 6 months in duration for calculation